JP2008501778A - 疼痛の治療のためのレボキセチンの使用 - Google Patents

疼痛の治療のためのレボキセチンの使用 Download PDF

Info

Publication number
JP2008501778A
JP2008501778A JP2007526596A JP2007526596A JP2008501778A JP 2008501778 A JP2008501778 A JP 2008501778A JP 2007526596 A JP2007526596 A JP 2007526596A JP 2007526596 A JP2007526596 A JP 2007526596A JP 2008501778 A JP2008501778 A JP 2008501778A
Authority
JP
Japan
Prior art keywords
pain
reboxetine
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007526596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501778A5 (enExample
Inventor
バーナデット・ヒューズ
イーアン・マケンジー
マルカム・ジョン・ストーカー
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2008501778A publication Critical patent/JP2008501778A/ja
Publication of JP2008501778A5 publication Critical patent/JP2008501778A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007526596A 2004-06-09 2005-05-27 疼痛の治療のためのレボキセチンの使用 Withdrawn JP2008501778A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
US58865204P 2004-07-16 2004-07-16
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2008501778A true JP2008501778A (ja) 2008-01-24
JP2008501778A5 JP2008501778A5 (enExample) 2008-07-10

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526596A Withdrawn JP2008501778A (ja) 2004-06-09 2005-05-27 疼痛の治療のためのレボキセチンの使用

Country Status (12)

Country Link
US (1) US20080261984A1 (enExample)
EP (1) EP1763354A2 (enExample)
JP (1) JP2008501778A (enExample)
KR (1) KR20070029740A (enExample)
AU (1) AU2005256944A1 (enExample)
BR (1) BRPI0511941A (enExample)
CA (1) CA2567365A1 (enExample)
IL (1) IL178827A0 (enExample)
MX (1) MXPA06014389A (enExample)
NO (1) NO20064642L (enExample)
RU (1) RU2006143659A (enExample)
WO (1) WO2006000903A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
MX2020010938A (es) * 2018-04-17 2021-01-29 Shanghai Tonglian Pharmaceutical Co Ltd Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo.
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20190381056A1 (en) * 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
WO2020081461A1 (en) * 2018-10-15 2020-04-23 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20240415842A1 (en) * 2019-12-03 2024-12-19 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1667686A1 (en) * 2003-09-09 2006-06-14 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
WO2005025675A1 (en) * 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors

Also Published As

Publication number Publication date
WO2006000903A3 (en) 2006-06-08
WO2006000903A2 (en) 2006-01-05
MXPA06014389A (es) 2007-02-19
CA2567365A1 (en) 2006-01-05
US20080261984A1 (en) 2008-10-23
KR20070029740A (ko) 2007-03-14
AU2005256944A1 (en) 2006-01-05
EP1763354A2 (en) 2007-03-21
BRPI0511941A (pt) 2008-01-22
RU2006143659A (ru) 2008-06-20
NO20064642L (no) 2006-11-13
IL178827A0 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
CN103179962B (zh) 丙二腈酰胺类似物在神经病理性疼痛中的用途
MXPA06003157A (es) Combinaciones de ligandos alfa-2-delta e inhibidores de la acetilcolina esterasa.
RU2537137C2 (ru) Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
ES2532950T3 (es) Composición farmacéutica con los principios activos metformina y sitagliptina o vildagliptina
PT1536782E (pt) Combinação sinérgica de um ligando alfa-2-delta e um inibidor pdev para ser utilizada no tratamento da dor
JP2024540282A (ja) シロシビン類似体の製剤および使用方法
JP2001510154A (ja) カッパアゴニスト化合物、製剤、ならびにそれらによる掻痒の予防法および治療法
MX2012014087A (es) Composiciones farmaceuticas de co- cristales de tramadol y coxibs.
JP2008501778A (ja) 疼痛の治療のためのレボキセチンの使用
JP2012144545A (ja) アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
JP2024069257A (ja) Ｌ－４－クロロキヌレニンの剤形及び治療的使用
ES2987503T3 (es) Compuestos que tienen afinidad por el receptor de melatonina como agente profiláctico o terapéutico para el delirio confusional
JP2007527905A (ja) アルファ−２−デルタリガンドを含む組合せ
JP2023503088A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
JP2015516452A (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物
JP2025514861A (ja) 血漿カリクレイン阻害剤の製剤
CN101208095A (zh) 瑞波西汀在治疗疼痛中的应用
NZ571251A (en) Renin inhibitors such as aliskiren for the treatment of rebound hypertension
HK1113092A (en) Use of reboxetine for the treatment of pain
JP2008255064A (ja) 睡眠障害予防治療剤
JP7709202B2 (ja) 睡眠障害を伴うｃｎｓ障害の治療
JPWO2001013911A1 (ja) 高血圧性細動脈障害抑制剤
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤
CN114080221A (zh) 用于减轻疼痛的布洛芬与曲马多的组合
JP2022529290A (ja) 呼吸性不整脈を処置するための方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080522

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081110

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081127

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090107